A Phase 3 interventional study of Benralizumab and Placebo in Hypereosinophilic Syndrome, sponsored by AstraZeneca. Active, not recruiting at 52 sites in 17 countries. Open to participants aged 12 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-07-10.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Hypereosinophilic Syndrome with a site in United States — 3 open to participants now, 8 under way, 3 of them phase 3. Hypereosinophilic Syndrome · United States.
Among the 23 studies in Hypereosinophilic Syndrome with a site in United States, this one is the 3rd largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2020, is one of 8 in phase 3, and was the 18th registered.
40 studies on the registry are indexed under Hypereosinophilic Syndrome; 8 are open to participants now.
Browse Hypereosinophilic Syndrome studies →3 of the 23 studies in Hypereosinophilic Syndrome with a site in United States are open now. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–99
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 1–100 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Hypereosinophilic Syndrome studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 12 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 8 · Phase 4 1
First in 1998; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 134 is above the median of 41 across 31 interventional studies indexed under Hypereosinophilic Syndrome.
Median enrollment 68 across the 21 interventional studies, 150 across the 2 observational. Of the 14 that completed or were terminated, 8 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 23 have an industry lead sponsor. The 9 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 3 studies filed under Hypereosinophilic Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Hypereosinophilic Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05334368Phase 3GlaxoSmithKlineDepemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial | 2027-10-29 |
| NCT06477653National Institute of Allergy and Infectious Diseases (NIAID)Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents | 2026-12-30 |
| NCT03862157M.D. Anderson Cancer CenterAzacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | 2027-01-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Hypereosinophilic Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicentre, randomised, double-blind (DB), parallel-group, placebo-controlled, 24-week Phase III study to compare the efficacy and safety of benralizumab versus placebo administered by SC injection Q4W in patients with hypereosinophilic syndrome (HES). This study comprises 2 distinct periods (together defined as the 'main study'): A 24-week, DB treatment period, during which patients will be randomised to receive either benralizumab or placebo, in addition to their prior stable HES background therapy, and an open-label extension (OLE) period, during which all patients will receive benralizumab.
The primary database lock (DBL) will occur when approximately 38 patients have had their first HES worsening/flare event during the DB treatment period and all randomised patients have had the opportunity to be followed up for the 24-week DB treatment period.
A patient must complete the 24-week DB treatment period on investigational product (IP) to be eligible to enter the OLE treatment period. The final DBL will occur after the last patient completes the OLE.
This is a multicentre, randomised, DB, parallel-group, placebo-controlled, 24-week Phase III study to compare the efficacy and safety of benralizumab 30 mg versus placebo administered by SC injection Q4W in patients with HES. This study will be conducted at approximately 68 sites in 18 countries.
The target patient population is male and female patients 12 years of age and older with symptomatic active HES. Eligible patients must be negative for the FIP1L1-PDGFRA fusion tyrosine kinase gene translocation.
Potentially eligible patients will enter a 3-day screening period and will be required to have documented stable HES therapy for at least 4 weeks prior to Visit 1 and AEC ≥ 1000 cells/μL at local laboratory testing to proceed to the second day of the screening period. Patients will be assessed for corticosteroid responsiveness (defined as an AEC \< 1000 cells/μL after 2 days of OCS [prednisone/prednisolone] 1 mg/kg/day given on top of the patient's background therapy for HES) prior to randomisation; other OCSs in equivalent doses are permitted. Patients who are not corticosteroid responsive or fail any other eligibility criteria will be screen failed.
It is expected that approximately 120 patients will be randomised at a 1:1 ratio at the randomisation/baseline visit (Visit 3) to receive either benralizumab or matching placeboQ4W for a 24-week DB treatment period. Recruitment may continue beyond 120 patients if required to achieve the target number of HES worsening/flares. Recruitment of adolescent patients is targeted to be broadly in line with expected prevalence rates of adolescents in the overall population. Approximately 4 to 6 adolescent patients (aged 12 to 17) are targeted to be randomised. Randomisation will be stratified. Approximately 40 patients will participate in a noninterventional interview to collect data on HRQoL and the patients' experience during the DB portion of the study.
All patients will remain on stable dose(s) and regimen of background HES therapy during the screening period and throughout 36 weeks of treatment (until Visit 12/Week 36 when the therapy can be adjusted). During this time, background HES therapy may only be modified if a patient has an HES clinical worsening/flare or an AE thought to be due to background therapy.
AstraZeneca, sites, and patients will be blinded to the absolute eosinophil, basophil, and monocyte counts, differential blood counts (percentages) for all WBCs (eosinophils, basophils, monocytes, neutrophils, and lymphocytes), and biopsy cell counts (if applicable) after randomisation/baseline (Visit 3/Week 0), during the entire DB treatment period, and for the first 4 weeks of the OLE treatment period (until Visit 10/Week 28) after which no blinding to WBC counts or biopsy cell counts is required. After the primary DBL, AstraZeneca will become unblinded to all patients' blood and biopsy cell counts obtained during DB treatment period.
The final dose of the DB treatment period will be given at Week 20, and the DB treatment period will complete at Week 24.
All patients who complete the DB treatment period on IP may be eligible to continue into an OLE treatment period on benralizumab (30 mg SC Q4W). The OLE is intended to allow treatment with open-label benralizumab for at least 1 year for adults and at least 2 years for adolescents after completion of the DB treatment period of the study (earlier enrolled patients may therefore be in the OLE for longer than 1 year). AstraZeneca may choose to extend the study depending on the overall development program. Moreover, AstraZeneca reserves the right of terminating the OLE early (eg, if development of the asset is terminated or marketing authorisation is obtained).
The primary DBL will occur when approximately 38 patients have had their first HES worsening/flare event during the DB treatment period and all randomised patients have had the opportunity to be followed up for the 24-week DB treatment period. Treatment allocation will remain blinded until the primary DBL. A patient must complete the 24-week DB treatment period on IP to be eligible to enter the OLE treatment period. The final DBL will occur after the last patient completes the OLE. Data from the OLE treatment period of the study will be presented in an addendum to the primary analysis CSR and/or a separate OLE treatment period CSR.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Signs or symptoms of HES worsening/flare and/or laboratory abnormalities indicative of HES worsening/flare (other than isolated eosinophilia) at Visit 1 OR a documented history of 2 or more HES worsening/flares within 12 months prior to Visit 1 requiring an escalation in therapy
a. At least one flare within the past 12 months must not be related to a decrease in HES therapy during the 4 weeks prior to the flare
must agree to use a highly effective method of (confirmed by the investigator) from enrolment, throughout the study duration, and within 12 weeks after last dose of IP and have a negative urine dipstick pregnancy test result on Visit 1. Highly effective methods of birth control (those that can achieve a failure rate of less than 1% per year when used consistently and correctly) include:
Exclusion Criteria
Life-threatening HES and/or HES complication(s) as judged by the investigator:
Known currently active liver disease
Current or history of within 5 years before the screening visit with the following exceptions:
14. Evidence of prior benralizumab treatment failure
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1x Benralizumab SC injection
Biological: Benralizumab
1x Benralizumab matching placebo SC injection
Biological: Placebo
Benralizumab solution for injection in an accessorised prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks
Matching placebo solution for injection in an APFS will be administered SC every 4 weeks
Time to First HES Worsening/Flare During the DB Treatment Period
The time to first HES worsening/flare is calculated as: start date of the first HES worsening - date of randomisation + 1. For participants who do not experience a HES worsening/flare, the time to first HES worsening/flare is right censored at the end of the DB period corresponding to the earliest date (date of the first of Benra open label dose, study day 183, date of last contact, and data cut-off date). The number of participants with events and censored observations is presented.
Time frame: DB period (Baseline to Week 24)
Proportion of Patients Who Experience an HES Worsening/Flare During the DB Treatment Period
The proportion of participants who experience an HES worsening/flare or who withdraw from the study prior to completing the 24-week DB treatment period. The proportion is calculated as the number of participants with an HES worsening/flare or withdrawal divided by the total number of participants in the analysis population. The number and proportion (expressed as percentage) or participants who experienced HES worsening/flare is presented.
Time frame: DB period (Baseline to Week 24)
Number of HES Worsenings/Flares (Annualised Rate) During the DB Period
The annualised rate of HES worsening/flare events was analysed using a negative binomial regression model adjusted for region, with the logarithm of follow-up time included as an offset variable. Annualized flare rates are model estimated marginal rates. A separate HES worsening/flare is considered if the start date of an HES worsening/flare is at least 14 days apart from the stop date of a preceding HES worsening/flare.
Time frame: DB period (Baseline to Week 24)
Time to First Haematologic Relapse (AEC ≥ 1000 Cells/μL) During the DB Period
Time to first haematologic relapse is calculated as start date of the first haematologic relapse - date of randomisation + 1. Haematologic relapse is defined as the first occurrence of an absolute eosinophil count (AEC) ≥ 1000 cells/μL post-baseline. For participants who do not experience haematologic relapse, the time to first haematologic relapse is right censored at the end of the DB period corresponding to the earliest date of (date of the first of Benra open label dose, study day 183, date of last contact, and data cut-off date). The number of participants with events and censored observations is presented.
Time frame: DB period (Baseline to Week 24)
Fatigue Severity (PROMIS Fatigue Short Form 7a) at Week 24
Fatigue severity was assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 7a questionnaire. Each item is scored on a 5-point Likert scale (1 to 5), and the total raw score is converted to a T-score. T-scores are standardized such that 50 represents the population mean with a standard deviation of 10. Standardized T-score range is from 29.4 to 83.2, with higher scores indicating more severe fatigue. A reduction in T-score indicates an improvement in fatigue severity. The least squares (LS) mean (95% CI) change from baseline in T-score at Week 24 is presented.
Time frame: Week 24
Proportion of Patients Who Have Haematologic Relapse During the DB Treatment Period
The proportion of patients who have a haematologic relapse or withdraw from the study over the DB treatment period is defined as the number of participants who have a first haematologic relapse or withdraw prior to completing in the DB period divided by the number of participants in the the analysis. Haematologic relapse is defined when AEC post baseline is ≥ 1,000 cells/Ul for the first time. The number and proportion (expressed as percentage) of participants who experienced haematologic relapse is presented.
Time frame: DB period (Baseline to Week 24)
Proportion of Patients Who Have AEC < 500 Cells/μL for 24 Weeks
The proportion of participants who maintained an AEC of \< 500 cells/µL throughout the 24-week DB treatment period. The proportion is defined as the number of participants who maintained AEC \< 500 cells/µL divided by the total number of participants in the analysis population. The number and proportion (expressed as percentage) of participants who maintained AEC \< 500 cells/µL is presented.
Time frame: DB period (Baseline to Week 24)
Proportion of Patients Who Require an Increase in Corticosteroid Dose From Baseline at Any Point in the DB Treatment Period
The proportion of patients who required an increase in systemic corticosteroids (SCS) from baseline during the 24-week DB treatment period. An increase in SCS includes an increase of at least 1 mg prednisone equivalent for participants receiving oral corticosteroids at baseline, or initiation of a new or additional course of systemic corticosteroids for treatment of HES or a closely related condition. Baseline is defined as the last valid value on or prior to randomisation. The number and proportion (expressed as percentage) of participants who require an increase in SCS from baseline.
Time frame: DB period (Baseline to Week 24)
Health-Related Quality of Life (HRQoL) (Short Form-36 Version 2 [SF-36v2])
HRQoL was assessed using the 36 Item Short Form Health Survey, version 2 (SF 36v2). Change from baseline in HRQoL was evaluated using the Physical Component Summary (PCS) and Mental Component Summary (MCS) scores at Week 12 and Week 24 during the DB treatment period. PCS and MCS scores are norm-based and standardized to a general population with a mean of 50 and a standard deviation of 10, with higher scores indicating better HRQoL. Scores generally range from 0 to 100. PCS and MCS scores are derived from weighted combinations of domain scores using standard scoring algorithms. An increase in score indicates an improvement. LS mean (95% CI) changes from baseline for PCS and MCS scores are presented.
Time frame: DB period (Baseline to Week 24)
Patient Global Impression of Severity (PGI-S)
Patient Global Impression of Severity (PGI-S) is a single-item, participant-reported assessment of disease severity during the DB treatment period. PGI-S captures the participant's perception of overall symptom severity at the time of assessment using categorical response options ranging from "No symptoms" to "Very severe". The number and percentage of participants in each response category are presented at each timepoint.
Time frame: DB period (Baseline to Week 24)
Patient Global Impression of Change (PGI-C)
Patient Global Impression of Change (PGI-C) is a single-item, participant-reported assessment that captures the participant's overall evaluation of response to treatment during the DB treatment period. PGI-C reflects the participant's perception of change in disease status compared with baseline using categorical response options ranging from "Much better" to "Much worse." The number and percentage of participants in each response category are presented at each time point.
Time frame: DB period (Baseline to Week 24)
Serum Benralizumab Concentrations
Serum concentrations of benralizumab measured over time during the DB period to characterise the pharmacokinetics of benralizumab in participants with HES. Baseline is defined as the last valid value on or prior to the date of randomisation.
Time frame: DB period (Baseline to Week 24)
Anti-Benralizumab Antibodies and Neutralizing Antibodies (nAbs)
Immunogenicity of benralizumab, as assessed by the incidence and prevalence of anti-drug antibodies (ADA), including nAbs, measured from baseline through the 24-week DB treatment period in participants with HES.
Time frame: DB period (Baseline to Week 24)
A total of 134 participants were randomized at 40 study centres across 15 countries. Of the 134 participants randomized, 133 received treatment during the 24-week double-blind (DB) period. One participant did not receive treatment due to withdrawal.
| Milestone | Benra | Placebo |
|---|---|---|
| Started | 67 | 66 |
| Completed | 65 | 62 |
| Not completed | 2 | 4 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Withdrawn from study due to severe non-compliance to protocol | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 4 |
| Milestone | Benra | Placebo |
|---|---|---|
| Started | 65 | 61 |
| Completed | 0 | 0 |
| Not completed | 65 | 61 |
| Withdrew: Ongoing | 56 | 50 |
| Withdrew: Withdrawal by subject | 6 | 4 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Withdrawal for other reason | 2 | 5 |
The time to first HES worsening/flare is calculated as: start date of the first HES worsening - date of randomisation + 1. For participants who do not experience a HES worsening/flare, the time to first HES worsening/flare is right censored at the end of the DB period corresponding to the earliest date (date of the first of Benra open label dose, study day 183, date of last contact, and data cut-off date). The number of participants with events and censored observations is presented.
| Participants | Benra | Placebo |
|---|---|---|
| Event | 13 | 28 |
| Censored | 54 | 38 |
The proportion of participants who experience an HES worsening/flare or who withdraw from the study prior to completing the 24-week DB treatment period. The proportion is calculated as the number of participants with an HES worsening/flare or withdrawal divided by the total number of participants in the analysis population. The number and proportion (expressed as percentage) or participants who experienced HES worsening/flare is presented.
| Participants | Benra | Placebo |
|---|---|---|
| Proportion of Patients Who Experience an HES Worsening/Flare During the DB Treatment Period | 15 | 30 |
The annualised rate of HES worsening/flare events was analysed using a negative binomial regression model adjusted for region, with the logarithm of follow-up time included as an offset variable. Annualized flare rates are model estimated marginal rates. A separate HES worsening/flare is considered if the start date of an HES worsening/flare is at least 14 days apart from the stop date of a preceding HES worsening/flare.
| flares per year | Benra | Placebo |
|---|---|---|
| Number of HES Worsenings/Flares (Annualised Rate) During the DB Period | 0.41 (0.24 to 0.71) | 1.23 (0.88 to 1.72) |
Time to first haematologic relapse is calculated as start date of the first haematologic relapse - date of randomisation + 1. Haematologic relapse is defined as the first occurrence of an absolute eosinophil count (AEC) ≥ 1000 cells/μL post-baseline. For participants who do not experience haematologic relapse, the time to first haematologic relapse is right censored at the end of the DB period corresponding to the earliest date of (date of the first of Benra open label dose, study day 183, date of last contact, and data cut-off date). The number of participants with events and censored observations is presented.
| Participants | Benra | Placebo |
|---|---|---|
| Event | 5 | 39 |
| Censored | 62 | 27 |
Fatigue severity was assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 7a questionnaire. Each item is scored on a 5-point Likert scale (1 to 5), and the total raw score is converted to a T-score. T-scores are standardized such that 50 represents the population mean with a standard deviation of 10. Standardized T-score range is from 29.4 to 83.2, with higher scores indicating more severe fatigue. A reduction in T-score indicates an improvement in fatigue severity. The least squares (LS) mean (95% CI) change from baseline in T-score at Week 24 is presented.
| T-score | Benra | Placebo |
|---|---|---|
| Fatigue Severity (PROMIS Fatigue Short Form 7a) at Week 24 | -8.6 (-10.6 to -6.6) | -3.9 (-6.0 to -1.8) |
The proportion of patients who have a haematologic relapse or withdraw from the study over the DB treatment period is defined as the number of participants who have a first haematologic relapse or withdraw prior to completing in the DB period divided by the number of participants in the the analysis. Haematologic relapse is defined when AEC post baseline is ≥ 1,000 cells/Ul for the first time. The number and proportion (expressed as percentage) of participants who experienced haematologic relapse is presented.
| Participants | Benra | Placebo |
|---|---|---|
| Proportion of Patients Who Have Haematologic Relapse During the DB Treatment Period | 6 | 42 |
The proportion of participants who maintained an AEC of \< 500 cells/µL throughout the 24-week DB treatment period. The proportion is defined as the number of participants who maintained AEC \< 500 cells/µL divided by the total number of participants in the analysis population. The number and proportion (expressed as percentage) of participants who maintained AEC \< 500 cells/µL is presented.
| Participants | Benra | Placebo |
|---|---|---|
| Proportion of Patients Who Have AEC < 500 Cells/μL for 24 Weeks | 61 | 8 |
The proportion of patients who required an increase in systemic corticosteroids (SCS) from baseline during the 24-week DB treatment period. An increase in SCS includes an increase of at least 1 mg prednisone equivalent for participants receiving oral corticosteroids at baseline, or initiation of a new or additional course of systemic corticosteroids for treatment of HES or a closely related condition. Baseline is defined as the last valid value on or prior to randomisation. The number and proportion (expressed as percentage) of participants who require an increase in SCS from baseline.
| Participants | Benra | Placebo |
|---|---|---|
| Proportion of Patients Who Require an Increase in Corticosteroid Dose From Baseline at Any Point in the DB Treatment Period | 17 | 32 |
HRQoL was assessed using the 36 Item Short Form Health Survey, version 2 (SF 36v2). Change from baseline in HRQoL was evaluated using the Physical Component Summary (PCS) and Mental Component Summary (MCS) scores at Week 12 and Week 24 during the DB treatment period. PCS and MCS scores are norm-based and standardized to a general population with a mean of 50 and a standard deviation of 10, with higher scores indicating better HRQoL. Scores generally range from 0 to 100. PCS and MCS scores are derived from weighted combinations of domain scores using standard scoring algorithms. An increase in score indicates an improvement. LS mean (95% CI) changes from baseline for PCS and MCS scores are presented.
| T-score | Benra | Placebo |
|---|---|---|
| PCS (Week 12) | 5.2 (3.6 to 6.9) | 2.2 (0.5 to 3.8) |
| PCS (Week 24) | 6.7 (4.9 to 8.5) | 2.2 (0.3 to 4.0) |
| MCS (Week 12) | 5.4 (3.4 to 7.3) | 1.0 (-1.0 to 3.0) |
| MCS (Week 24) | 5.3 (3.2 to 7.3) | 2.7 (0.5 to 4.8) |
Patient Global Impression of Severity (PGI-S) is a single-item, participant-reported assessment of disease severity during the DB treatment period. PGI-S captures the participant's perception of overall symptom severity at the time of assessment using categorical response options ranging from "No symptoms" to "Very severe". The number and percentage of participants in each response category are presented at each timepoint.
| Participants | Benra | Placebo |
|---|---|---|
| Baseline — No symptoms | 4 | 4 |
| Baseline — Very mild | 10 | 8 |
| Baseline — Mild | 10 | 11 |
| Baseline — Moderate | 30 | 19 |
| Baseline — Severe | 10 | 21 |
| Baseline — Very severe | 3 | 2 |
| Week 4 — No symptoms | 13 | 7 |
| Week 4 — Very mild | 12 | 10 |
| Week 4 — Mild | 22 | 17 |
| Week 4 — Moderate | 16 | 22 |
| Week 4 — Severe | 3 | 6 |
| Week 4 — Very severe | 0 | 2 |
| Week 8 — No symptoms | 15 | 8 |
| Week 8 — Very mild | 19 | 14 |
| Week 8 — Mild | 14 | 11 |
| Week 8 — Moderate | 12 | 22 |
| Week 8 — Severe | 3 | 7 |
| Week 8 — Very severe | 1 | 0 |
| Week 12 — No symptoms | 22 | 9 |
| Week 12 — Very mild | 18 | 13 |
| Week 12 — Mild | 15 | 17 |
| Week 12 — Moderate | 7 | 17 |
| Week 12 — Severe | 4 | 4 |
| Week 12 — Very severe | 0 | 1 |
| Week 16 — No symptoms | 17 | 9 |
| Week 16 — Very mild | 14 | 15 |
| Week 16 — Mild | 20 | 14 |
| Week 16 — Moderate | 8 | 16 |
| Week 16 — Severe | 4 | 4 |
| Week 16 — Very severe | 0 | 3 |
| Week 20 — No symptoms | 16 | 7 |
| Week 20 — Very mild | 17 | 17 |
| Week 20 — Mild | 15 | 17 |
| Week 20 — Moderate | 11 | 15 |
| Week 20 — Severe | 5 | 4 |
| Week 20 — Very severe | 0 | 1 |
| Week 24 — No symptoms | 17 | 11 |
| Week 24 — Very mild | 17 | 16 |
| Week 24 — Mild | 13 | 14 |
| Week 24 — Moderate | 13 | 12 |
| Week 24 — Severe | 4 | 6 |
| Week 24 — Very severe | 0 | 0 |
Patient Global Impression of Change (PGI-C) is a single-item, participant-reported assessment that captures the participant's overall evaluation of response to treatment during the DB treatment period. PGI-C reflects the participant's perception of change in disease status compared with baseline using categorical response options ranging from "Much better" to "Much worse." The number and percentage of participants in each response category are presented at each time point.
| Participants | Benra | Placebo |
|---|---|---|
| Week 4 — Much better | 17 | 8 |
| Week 4 — Moderately better | 9 | 8 |
| Week 4 — A little better | 18 | 13 |
| Week 4 — About the same | 19 | 27 |
| Week 4 — A little worse | 1 | 3 |
| Week 4 — Moderately worse | 2 | 3 |
| Week 4 — Much worse | 0 | 1 |
| Week 8 — Much better | 20 | 7 |
| Week 8 — Moderately better | 12 | 11 |
| Week 8 — A little better | 18 | 14 |
| Week 8 — About the same | 12 | 22 |
| Week 8 — A little worse | 1 | 3 |
| Week 8 — Moderately worse | 1 | 3 |
| Week 8 — Much worse | 0 | 2 |
| Week 12 — Much better | 26 | 9 |
| Week 12 — Moderately better | 15 | 11 |
| Week 12 — A little better | 16 | 12 |
| Week 12 — About the same | 7 | 22 |
| Week 12 — A little worse | 2 | 3 |
| Week 12 — Moderately worse | 0 | 2 |
| Week 12 — Much worse | 0 | 1 |
| Week 16 — Much better | 26 | 12 |
| Week 16 — Moderately better | 13 | 12 |
| Week 16 — A little better | 8 | 7 |
| Week 16 — About the same | 10 | 20 |
| Week 16 — A little worse | 3 | 3 |
| Week 16 — Moderately worse | 2 | 5 |
| Week 16 — Much worse | 0 | 2 |
| Week 20 — Much better | 24 | 14 |
| Week 20 — Moderately better | 15 | 6 |
| Week 20 — A little better | 10 | 13 |
| Week 20 — About the same | 10 | 20 |
| Week 20 — A little worse | 3 | 4 |
| Week 20 — Moderately worse | 2 | 4 |
| Week 20 — Much worse | 0 | 0 |
| Week 24 — Much better | 27 | 14 |
| Week 24 — Moderately better | 12 | 6 |
| Week 24 — A little better | 13 | 8 |
| Week 24 — About the same | 9 | 22 |
| Week 24 — A little worse | 0 | 6 |
| Week 24 — Moderately worse | 3 | 2 |
| Week 24 — Much worse | 0 | 0 |
Serum concentrations of benralizumab measured over time during the DB period to characterise the pharmacokinetics of benralizumab in participants with HES. Baseline is defined as the last valid value on or prior to the date of randomisation.
| ng/mL | Benra |
|---|---|
| Baseline | 3.699 ± 16.906 |
| Week 4 | 748.176 ± 238.842 |
| Week 8 | 1384.403 ± 133.177 |
| Week 16 | 1467.213 ± 184.478 |
| Week 24 | 1764.068 ± 130.601 |
Immunogenicity of benralizumab, as assessed by the incidence and prevalence of anti-drug antibodies (ADA), including nAbs, measured from baseline through the 24-week DB treatment period in participants with HES.
| Participants | Benra | Placebo |
|---|---|---|
| ADA negative (negative at all visits, baseline and post-baseline) | 59 | 57 |
| ADA positive at baseline and/or post-baseline (prevalence) | 8 | 9 |
| ADA positive only at baseline | 0 | 0 |
| ADA positive at both baseline and ≥ one post-baseline | 3 | 5 |
| Treatment-emergent (TE) ADA positive/ADA incidence | 7 | 8 |
| Non-treatment-emergent ADA positive | 1 | 1 |
| Persistently positive ADA | 3 | 1 |
| Transiently positive ADA | 2 | 3 |
| TE-ADA positive with maximum post-baseline titre > median of maximum post-baseline titre | 4 | 3 |
| nAb prevalence | 3 | 5 |
| nAb incidence | 2 | 3 |
Collected over DB Treatment Period: From the first dose of investigational product (IP) through the end of the 24-week DB period. OLE Period: From the first dose of benralizumab in the OLE period (following completion of the DB period at Week 24) to the data cut-off date 07 May 2025. The duration of follow-up varied by participant, up to approximately 4.3 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Benra - DB | 1/67 (1.5%) | 5/67 (7.5%) | 23/67 (34.3%) |
| Placebo - DB | 0/66 (0%) | 5/66 (7.6%) | 18/66 (27.3%) |
| Benra - OLE | 0/65 (0%) | 11/65 (16.9%) | 42/65 (64.6%) |
| Placebo Switched to Benra - OLE | 0/61 (0%) | 10/61 (16.4%) | 45/61 (73.8%) |
| Event | Benra - DB | Placebo - DB | Benra - OLE | Placebo Switched to Benra - OLE |
|---|---|---|---|---|
| CholelithiasisHepatobiliary disorders | 0/67 | 0/66 | 0/65 | 1/61 |
| Acquired haemophiliaBlood and lymphatic system disorders | 0/67 | 0/66 | 0/65 | 1/61 |
| Hypereosinophilic syndromeBlood and lymphatic system disorders | 1/67 | 1/66 | 0/65 | 1/61 |
| BradycardiaCardiac disorders | 0/67 | 0/66 | 0/65 | 1/61 |
| IntussusceptionGastrointestinal disorders | 0/67 | 0/66 | 0/65 | 1/61 |
| CellulitisInfections and infestations | 0/67 | 0/66 | 0/65 | 1/61 |
| GastroenteritisInfections and infestations | 0/67 | 0/66 | 0/65 | 1/61 |
| Infective exacerbation of asthmaInfections and infestations | 0/67 | 0/66 | 0/65 | 1/61 |
| Pneumonia bacterialInfections and infestations | 0/67 | 1/66 | 0/65 | 1/61 |
| Urinary tract infectionInfections and infestations | 0/67 | 0/66 | 0/65 | 1/61 |
| Event | Benra - DB | Placebo - DB | Benra - OLE | Placebo Switched to Benra - OLE |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 5/67 | 5/66 | 15/65 | 15/61 |
| Covid-19Infections and infestations | 4/67 | 4/66 | 11/65 | 13/61 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/67 | 5/66 | 6/65 | 11/61 |
| HeadacheNervous system disorders | 11/67 | 5/66 | 5/65 | 9/61 |
| NasopharyngitisInfections and infestations | 3/67 | 4/66 | 9/65 | 6/61 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/67 | 0/66 | 6/65 | 5/61 |
| DiarrhoeaGastrointestinal disorders | 0/67 | 0/66 | 6/65 | 5/61 |
| VomitingGastrointestinal disorders | 0/67 | 0/66 | 3/65 | 5/61 |
| GastroenteritisInfections and infestations | 0/67 | 0/66 | 5/65 | 5/61 |
| RhinitisInfections and infestations | 0/67 | 0/66 | 2/65 | 5/61 |
Full Analysis Set: All participants who were randomized and received at least 1 dose of IP, irrespective of their protocol adherence and continued participation in the study.
| Age, Continuous(years) | Benra | Placebo | Total |
|---|---|---|---|
| Mean | 47.5 ± 18.62 | 49.2 ± 18.86 | 48.4 ± 18.68 |
| Age, Customized(Participants) | Benra | Placebo | Total |
|---|---|---|---|
| >=12 - <18 years | 3 | 1 | 4 |
| >=18 - <=21 years | 6 | 6 | 12 |
| >21 - <=50 years | 26 | 23 | 49 |
| >50 - <=65 years | 19 | 22 | 41 |
| >65 - <=75 years | 10 | 9 | 19 |
| >75 years | 3 | 5 | 8 |
| Sex: Female, Male(Participants) | Benra | Placebo | Total |
|---|---|---|---|
| Female | 43 | 39 | 82 |
| Male | 24 | 27 | 51 |
| Ethnicity (NIH/OMB)(Participants) | Benra | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 66 | 65 | 131 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Benra | Placebo | Total |
|---|---|---|---|
| White | 42 | 45 | 87 |
| Black or African American | 3 | 1 | 4 |
| Asian | 10 | 11 | 21 |
| Other | 3 | 0 | 3 |
| Not Reported | 9 | 9 | 18 |
| Region of Enrollment(Participants) | Benra | Placebo | Total |
|---|---|---|---|
| North America | 12 | 9 | 21 |
| Europe | 45 | 45 | 90 |
| Asia | 10 | 11 | 21 |
| Rest of World | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jul 2020 to primary completion in May 2025, 57 months.
Results were first posted in Jul 2026, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benralizumab